Atopic Eczema Clinical Trial
Official title:
A Pilot Study of Efficacy and Safety of a Microbiome Immunity Formula (SIM05) in Adults With Atopic Eczema
Atopic eczema causes significant disease burdens worldwide. Some studies reported gastrointestinal symptoms in eczema patients which could be related to gut microbiota change. A unique gastrointestinal microflora pattern has also been observed in atopic dermatitis patients when compared with healthy controls. To date, no adult formula is specific for alleviating atopic eczema-related symptoms (especially through change of gut microbiota) for adults. The investigators hypothesize that the gut microbiota of adults with atopic eczema can be modulated to decrease the severity of atopic eczema-related symptoms. A pilot study is proposed to assess the effect and safety of SIM05 on atopic eczema severity and gut microbiome of adults with atopic eczema.
The major atopic disorders, atopic eczema, allergic rhinitis and asthma, cause significant disease burdens worldwide. Apart from cutaneous symptoms such as dryness and itchiness in eczema patients [4], studies also reported gastrointestinal symptoms which could be related to gut microbiota change. Unique gastrointestinal microflora pattern has also been observed in atopic dermatitis patients when compared with healthy controls: decreased Bifidobacterium and Enterococci, especially Bifidobacterium bifidum and Bifidobacterium longum, and increased Faecalibacterium have been observed. Therefore, gastrointestinal microflora can serve as the disease indicator of atopic eczema. Emerging evidence also suggests that gut microbiota modulation can largely affect host immune functions in adults. To date, no adult formula is specific for alleviating atopic eczema-related symptoms (especially through change of gut microbiota) for adults. SIM05 contains a blend of naturally occurring three food-grade probiotics strains and three prebiotics. The three probiotics belong to food-grade Bifidobacterium and Lactobacillus, which is an important group of probiotic cultures commonly used in food products. Moreover, research showed that Lactobacillus and Bifidobacteria could prevent atopic sensitisation to common food allergens and thus reducing the incidence of atopic eczema. The investigators hypothesize that the gut microbiota of adult with atopic eczema can be modulated to decrease the severity of atopic eczema related symptoms. A pilot study of 30 adults with atopic eczema who will receive SIM05 for 16 weeks is proposed to assess the effect and safety of SIM05 on atopic eczema severity and gut microbiome. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02381028 -
Topical Treatment With Fresh Human Milk Versus Emollient on Atopic Eczema Spots in Young Children
|
N/A | |
| Completed |
NCT00484003 -
A Quality of Life and Safety Study With Pimecrolimus Cream, 1% in Children (Age 2-12 Years) With Atopic Dermatitis
|
Phase 4 | |
| Recruiting |
NCT05454722 -
A Study to Evaluate Adex Gel in the Treatment of Atopic Eczema.
|
N/A | |
| Completed |
NCT01854580 -
Evaluation of an Integrated Care Project
|
||
| Completed |
NCT00555178 -
Regulatory T Cells (Tregs) in Polymorphic Light Eruption
|
N/A | |
| Completed |
NCT00559546 -
Montelukast as a Controller of Atopic Syndrome
|
Phase 4 | |
| Completed |
NCT00224432 -
Double-Blind, Parallel, Randomised Study to Investigate the Effect of Oral Probiotics in Infants With Atopic Dermatitis
|
N/A | |
| Active, not recruiting |
NCT03143504 -
A Longitudinal Investigation of Skin Barrier Development From Birth and the Validation of Early Predictors of Atopic Eczema Risk: the Skin Testing for Atopic Eczema Risk (STAR) Study
|
||
| Active, not recruiting |
NCT03409367 -
A Community-based Assessment of Skin Care, Allergies, and Eczema
|
N/A | |
| Completed |
NCT00826592 -
Comparison of Video-Based Versus Written Patient Education on Atopic Dermatitis
|
N/A | |
| Completed |
NCT00576238 -
Skin Tolerance Study of Betamethasone Creams in Atopic Eczema and the Preventative Properties of a Moisturiser
|
Phase 3 | |
| Recruiting |
NCT05590585 -
Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial
|
Phase 4 | |
| Completed |
NCT01119313 -
Study to Investigate Skin Conditions and Patient Assessment of LAS 41002 in the Treatment of Atopic Eczema
|
Phase 2 | |
| Completed |
NCT00676884 -
A Phase 2a Study to Investigate the Effects of Repeated Administration of AeroDerm in Subjects With Atopic Eczema
|
Phase 2 | |
| Recruiting |
NCT03270566 -
Softened Water for Eczema Prevention Pilot Trial
|
N/A | |
| Completed |
NCT02300701 -
Role of Anti-IgE in Severe Childhood Eczema
|
Phase 4 | |
| Completed |
NCT04114097 -
The Effects of Topical Corticosteroid Use on Insulin Sensitivity and Bone Turnover
|
Phase 4 | |
| Completed |
NCT02915146 -
Narrowband Ultraviolet B Versus Narrowband Ultraviolet B Plus Ultraviolet A1 for Atopic Eczema
|
N/A | |
| Recruiting |
NCT00771121 -
Effect of Moisturizing Creams on Skin Barrier Function
|
Phase 4 | |
| Completed |
NCT01179529 -
Atopic Dermatitis Biomarker Identification Trial in Omalizumab Usage
|
Phase 2 |